Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$0.52.

  • ARS Pharmaceuticals' EPS (Basic) fell 16000.0% to -$0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.82, marking a year-over-year decrease of 6078.43%. This contributed to the annual value of $0.08 for FY2024, which is 11447.5% up from last year.
  • ARS Pharmaceuticals' EPS (Basic) amounted to -$0.52 in Q3 2025, which was down 16000.0% from -$0.46 recorded in Q2 2025.
  • ARS Pharmaceuticals' EPS (Basic)'s 5-year high stood at $0.49 during Q4 2024, with a 5-year trough of -$0.52 in Q3 2025.
  • Its 4-year average for EPS (Basic) is -$0.2, with a median of -$0.2 in 2024.
  • In the last 5 years, ARS Pharmaceuticals' EPS (Basic) soared by 79554.99% in 2024 and then crashed by 25384.62% in 2025.
  • Over the past 4 years, ARS Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.39 in 2022, then soared by 81.89% to -$0.07 in 2023, then soared by 795.55% to $0.49 in 2024, then plummeted by 206.8% to -$0.52 in 2025.
  • Its EPS (Basic) was -$0.52 in Q3 2025, compared to -$0.46 in Q2 2025 and -$0.35 in Q1 2025.